Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
New Pharma Vision to Set Out Clear Goal, KPIs after Lawmaker Calls
The Ministry of Health, Labor and Welfare (MHLW) plans to add a clear goal and key performance indicators (KPIs) to its new pharmaceutical industry vision due out later this month in a move responding to lawmakers’ calls. The vision will…
To read the full story
Related Article
- Japan Unveils New Pharma Industry Vision, 1st Update in 8 Years
September 14, 2021
- Pharma Leaders Support Draft Industry Vision, but Stress Need for Price Maintenance of Patented Meds: Confab
August 25, 2021
- Public-Private Dialogue for New Pharma Vision Set for Aug. 24
August 18, 2021
- Lawmakers See No Ultimate Goal in New Pharma Industry Vision
August 6, 2021
- New Pharma Industry Vision to Push Predictability for Investment Recovery: Draft Outline
August 3, 2021
REGULATORY
- Japan Has Limited Drug Pricing Cards to Play on MFN, Should Expand CEA: MOF Official
October 5, 2026
- RMPs to Become Statutory Requirement under PMD Act in May 2027
October 5, 2026
- Japan Panel Calls for Better Infrastructure to Expand RLT Access
October 5, 2026
- Drug Discovery Fund Cleared to Provide Funding to Startups
October 5, 2026
- MHLW Simplifies Repatha Optimal Use Guidelines
October 5, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…